Skynor Medical, a Shanghai-based manufacturer of nerve and peripheral blood vessel implantation and interventional devices, has reportedly raised RMB 100 million (USD 14.37 million) in a new financing round. Investors include Zhangjiang Hi-Tech Park Development, Pudong Capital, Zhangjiang Haoheng Innovative Equity Investment, and Suxin Venture Capital. The proceeds will be used to accelerate domestic and overseas market development and enhance product layout.
Company Background and Achievements
Founded in 2014, Skynor Medical has made significant progress this year. Its SkyVega blood flow-guided dense mesh stent has completed clinical enrollment, while its SkyFlow intracranial thrombosis stent, SkyLoach intracranial balloon catheter, SkySurfer remote access catheter, and other products have achieved high-tech milestones in transformation projects. The company’s peripheral interventional vascular stent has also concluded its follow-up. Skynor Medical’s business footprint now covers 29 provinces in China.
Future Prospects and Strategic Use of Funds
The financing round positions Skynor Medical to further expand its market presence both domestically and internationally. By investing in market development and product layout, the company aims to enhance its competitive edge and address significant unmet medical needs in the field of nerve and peripheral blood vessel interventions.-Fineline Info & Tech
